These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36447162)

  • 21. The challenge of multiple cardiovascular risk factor control outside Western Europe: Findings from the International ChoLesterol management Practice Study.
    Blom DJ; Santos RD; Daclin V; Mercier F; Ruiz AJ; Danchin N;
    Eur J Prev Cardiol; 2020 Sep; 27(13):1403-1411. PubMed ID: 31533447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of Obesity and Its Influence on Achievement of Cardiometabolic Therapeutic Goals in Chinese Type 2 Diabetes Patients: An Analysis of the Nationwide, Cross-Sectional 3B Study.
    Zhou X; Ji L; Ran X; Su B; Ji Q; Pan C; Weng J; Ma C; Hao C; Zhang D; Hu D; ;
    PLoS One; 2016; 11(1):e0144179. PubMed ID: 26726883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Women show worse control of type 2 diabetes and cardiovascular disease risk factors than men: results from the MIND.IT Study Group of the Italian Society of Diabetology.
    Franzini L; Ardigò D; Cavalot F; Miccoli R; Rivellese AA; Trovati M; Zavaroni I; Vaccaro O
    Nutr Metab Cardiovasc Dis; 2013 Mar; 23(3):235-41. PubMed ID: 22397873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients.
    Ji L; Hu D; Pan C; Weng J; Huo Y; Ma C; Mu Y; Hao C; Ji Q; Ran X; Su B; Zhuo H; Fox KA; Weber M; Zhang D; ;
    Am J Med; 2013 Oct; 126(10):925.e11-22. PubMed ID: 23810406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationships between obesity, glycemic control, and cardiovascular risk factors: a pooled analysis of cross-sectional data from Spanish patients with type 2 diabetes in the preinsulin stage.
    Vázquez LA; Rodríguez Á; Salvador J; Ascaso JF; Petto H; Reviriego J
    BMC Cardiovasc Disord; 2014 Nov; 14():153. PubMed ID: 25361574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Classical cardiovascular risk factors in Trinidadian patients with type 2 diabetes mellitus are not influenced by the level of plasma glycaemia.
    Ezenwaka CE; Offiah NV
    West Indian Med J; 2001 Dec; 50(4):288-93. PubMed ID: 11993019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glycemic Control and Cardiovascular Risk Factor Management in Adults With Type 2 Diabetes With and Without Chronic Kidney Disease Before Sodium-Glucose Cotransporter Protein 2 Inhibitors: Insights From the Diabetes Mellitus Status in Canada Survey.
    Nouraei H; Leiter LA; Tan MK; Langer A; Teoh H; Cheng AYY; Wald R; Connelly KA; Goodman SG; Yan AT
    Can J Diabetes; 2021 Dec; 45(8):743-749. PubMed ID: 33839025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Data on secondary prevention of coronary artery disease in Hungary and some changes in the last ten years (EUROASPIRE 1995-2005)].
    Jánosi A; Ostör E; Borbás S; Kazinczy R; Káli A; Vámos I; Bradák A; Podmaniczky M
    Orv Hetil; 2010 Oct; 151(43):1776-82. PubMed ID: 20940117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus.
    Fischer LT; Hochfellner DA; Knoll L; Pöttler T; Mader JK; Aberer F
    Cardiovasc Diabetol; 2021 Apr; 20(1):89. PubMed ID: 33894772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study.
    Banegas JR; López-García E; Dallongeville J; Guallar E; Halcox JP; Borghi C; Massó-González EL; Jiménez FJ; Perk J; Steg PG; De Backer G; Rodríguez-Artalejo F
    Eur Heart J; 2011 Sep; 32(17):2143-52. PubMed ID: 21471134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An audit of structured diabetes care in a rural general practice.
    Ackermann EW; Mitchell GK
    Med J Aust; 2006 Jul; 185(2):69-72. PubMed ID: 16842058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A cross-sectional study on the treatment goals of blood pressure, serum lipids and blood glucose in elderly patients with coronary heart disease].
    Zhu Y; Wang J; Bao Y; Qiao YX; Wu LZ; Li J; Li J; Hu DY
    Zhonghua Yi Xue Za Zhi; 2011 Jun; 91(21):1479-85. PubMed ID: 21914285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular risk factors in patients with type 2 diabetes. Do we follow the guidelines?
    del Cañizo-Gómez FJ; Moreira-Andrés MN
    Diabetes Res Clin Pract; 2004 Aug; 65(2):125-33. PubMed ID: 15223224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The role of nutritional factors in the formation of cardiovascular risk in patients with type 2 diabetes mellitus].
    Isakova DN; Dorodneva EF; Belokrylova LV; Kurmangulov AA; Petrov IM
    Vopr Pitan; 2021; 90(5):104-114. PubMed ID: 34719148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cardiovascular risk management in type-2 diabetes: Is the patients' cardiovascular risk adequately considered in type-2 specialist diabetes care?].
    Brenner S; Daikeler R; Oberaigner W; Stummer H
    Z Evid Fortbild Qual Gesundhwes; 2021 Dec; 167():6-14. PubMed ID: 34782254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyperglycemia and duration of diabetes as risk factors for abnormal lipids: a cross sectional survey of 19,757 patients with type 2 diabetes in China.
    Ji L; Weng J; Lu J; Guo X; Yang W; Jia W; Zou D; Zhou Z; Zhu D; Ji Q; Shi L; Yang X
    J Endocrinol Invest; 2014 Sep; 37(9):843-52. PubMed ID: 24963748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular Risk Factor Targets and Cardiovascular Disease Event Risk in Diabetes: A Pooling Project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart Study.
    Wong ND; Zhao Y; Patel R; Patao C; Malik S; Bertoni AG; Correa A; Folsom AR; Kachroo S; Mukherjee J; Taylor H; Selvin E
    Diabetes Care; 2016 May; 39(5):668-76. PubMed ID: 27208374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study.
    Paragh G; Márk L; Zámolyi K; Pados G; Ofner P
    Clin Drug Investig; 2007; 27(9):647-60. PubMed ID: 17705573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sex differences in cardiometabolic risk factors, pharmacological treatment and risk factor control in type 2 diabetes: findings from the Dutch Diabetes Pearl cohort.
    de Jong M; Oskam MJ; Sep SJS; Ozcan B; Rutters F; Sijbrands EJG; Elders PJM; Siegelaar SE; DeVries JH; Tack CJ; Schroijen M; de Valk HW; Abbink EJ; Stehouwer CDA; Jazet I; Wolffenbuttel BHR; Peters SAE; Schram MT;
    BMJ Open Diabetes Res Care; 2020 Oct; 8(1):. PubMed ID: 33023896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular risk factor management in patients with diabetes: Does management differ with disease duration?
    Lo S; Leiter LA; Langer A; Tan M; Goldin L; Harris S; Yale JF; Ekoe JM; Lin PJ; Goodman SG; Yan AT
    J Diabetes Complications; 2021 Oct; 35(10):107997. PubMed ID: 34332851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.